Hypera informed this Friday that it decided to reduce its payment term policy granted to customers, to optimize working capital, in addition to discontinuing its projections for the year, according to a relevant fact to the market.
The company said that this reduction aims to increase operating cash generation “potentially” by R$2.5 billion by 2028 and by R$7.5 billion over the next ten years.
According to the pharmaceutical group, the decision does not change the focus on its growth strategy in direct sales to consumers, the so-called “sell out” – which grew around 13% in October and approximately 11% in the third quarter – as well as on the diversification of portfolio.
READ MORE: Hypera sees potential market of R$10 billion with patent expiration
The company also released some preliminary results for the third quarter, ahead of the full earnings release scheduled for November 13th.
The preview of the result, unaudited and still subject to review, points to the company’s net revenue of around R$ 1.9 billion in the quarter ended in September, in addition to an Ebitda close to R$ 561 million and a net profit of around R$370 million.
Projections for 2024, which were discontinued, included a net revenue of close to R$8.6 billion, an adjusted EBITDA from continued operations of around R$3 billion and a net profit from continued operations close to R$1.85 billion.
Hypera, which has drug brands such as Buscopan, Coristina and Neosaldina in its portfolio, also announced in the same statement that its board of directors approved a buyback program of up to 30 million shares, with a term of 18 months and starting this Friday .
By Patricia Vilas Boas
